Abstract Alzheimer's disease (AD) is marked by an increase in the production of extracellular beta amyloid plaques and intracellular neurofibrillary tangles associated with a decline in brain function. Increases in oxidative stress are regarded as an early sign of AD pathophysiology, although the source of reactive oxygen species (ROS) and the mechanism(s) whereby beta amyloid peptides (Aβ) impact oxidative stress have not been adequately investigated. Recent studies provide strong evidence for the involvement of NADPH oxidase and its downstream oxidative signaling pathways in the toxic effects elicited by Aβ. ROS produced by NADPH oxidase activate multiple signaling pathways leading to neuronal excitotoxicity and glial cell-mediated inflammation. This review describes recent studies demonstrating the neurotoxic effects of Aβ in conjunction with ROS produced by NADPH oxidase and the downstream pathways leading to activation of cytosolic phospholipase A 2 (PLA 2 ) and secretory PLA 2 . In addition, this review also describes recent studies using botanical antioxidants to protect against oxidative damage associated with AD. Investigating the metabolic and signaling pathways involving Aβ NADPH oxidase and PLA 2 can help understand the mechanisms underlying the neurodegenerative effects of oxidative stress in AD. This information should provide new therapeutic approaches for prevention of this debilitating disease.
Increase in Oxidative Stress Is an Early Sign of AD Pathogenesis
Alzheimer's disease (AD) is the most prominent age-related neurodegenerative disease characterized by accumulation of beta amyloid plaques and intracellular neurofibrillary tangles in the brain. Impairment of cognitive function and memory in this disease is attributed to degeneration of synapses in specific brain regions [1] . Although manifestations of AD have been shown to involve multiple factors, including inherent genetic mutations and environmental conditions, increases in oxidative stress associated with amyloid beta peptide (Aβ) accumulation are considered important underlying factors in the development of this disease [2] [3] [4] [5] . Aβ peptides are comprised of 39-43 amino acids and are generated by proteolytic cleavage of amyloid precursor protein (APP) by beta and gamma secretases. Considerable evidence indicates that the cytotoxic effects of Aβ are due to its aggregation to the oligomeric form and not the monomeric or fibrillar forms [6] [7] [8] . Oligomeric Aβ can diffuse into cells and alter cellular pathways leading to disruption of synaptic plasticity and inhibition of long-term potentiation [9] . These abnormalities occur before the appearance of Aβ plaques [10] .
A number of studies have attempted to elucidate the mechanism(s) whereby Aβ enhances reactive oxygen species (ROS) production and stimulates oxidative signaling pathways in the AD brain. Studies using redox proteomics have identified oxidatively modified proteins as early markers of AD pathogenesis [11] . Earlier studies by Butterfield [12] implicated the possible role of methionine-35 residue of Aβ in conferring neurotoxicity. Transgenic PDAPP mice with an M631L mutation in the APP molecule (corresponding to M35 in Aβ) showed markedly decreased oxidative indices and immunoreactive plaques. Interestingly, this mutation did not prevent memory loss in this mouse model of AD [13] . In recent years, studies have provided compelling evidence for the role of oxidative stress in sustained inflammatory responses in the AD brain [14] [15] [16] [17] [18] [19] [20] . Novel strategies have been proposed to prevent neuronal damage due to oxidative stress [21] .
Phospholipases A 2 in AD-a Link to Oxidative and Pro-inflammatory Pathways
Phospholipases A 2 (PLA 2 ) are ubiquitous enzymes known for their role in the maintenance of cell membrane integrity and the production of lipid mediators that regulate cell functions [22, 23] . More than 20 species of PLA 2 are present in mammalian cells and are categorized as Ca 2+ -dependent cytosolic (cPLA 2 ), Ca 2+ -independent (iPLA 2 ), and secretory (sPLA 2 ) subtypes. In the central nervous system (CNS), PLA 2 activity has been implicated to play an important role in neurodegenerative diseases [24] . Recent studies also linked PLA 2 activity to ROS production and lipid peroxidation. A major objective of this review is to describe recent studies linking cPLA 2 and sPLA 2 to oxidative pathways in AD.
Cytosolic Phospholipase A2 In earlier studies, an increase in functional cPLA 2 protein or mRNA expression in AD brain has been demonstrated by immunohistochemical analysis [25, 26] , reverse transcriptase polymerase chain reaction [27] or detection of lipid hydrolysates [28] . cPLA 2 activity is regulated by a number of protein kinases, which phosphorylate the protein on specific serine residues. Extracellular signal-regulated kinase (ERK)-dependent cPLA 2 phosphorylation on Ser505 is critical for cPLA 2 activity [29] . However, studies to determine cPLA 2 activity in human AD brain have provided for contrasting results. For example, increases in levels of activated cPLA 2 were observed in the hippocampus of human AD brain and in the hAPP mouse model of AD [30] . The increase in cPLA 2 activity in AD brain was marked by the increase in 4-hydroxynonenal, an index of lipid peroxidation [31, 32] . On the contrary, other studies indicated a reduction in cPLA 2 activity in blood and brain samples from AD patients [33] . During the early stages of AD, cognitive impairment associated with aberrant cholinergic and glutamatergic activities has been linked to a decrease in both cPLA 2 and iPLA 2 activities [34] . A study utilizing magnetic resonance imaging also demonstrated reduced phospholipid turnover in the prefrontal cortex of AD patients [35] . Furthermore, decreased cPLA 2 activity was found in cerebrospinal fluid from AD, vascular, and mixed AD-vascular demented patients, as compared to healthy controls [33] . Although the reason for the differences in results is not yet clear, it is recognized that this enzyme is regulated by complex factors depending on the cell types and intracellular signaling pathways. Since cPLA 2 and its hydrolytic products are critically important in maintenance of phospholipids in cell membrane, more studies are needed to understand cell specific factors regulating cPLA 2 under physiological and pathological conditions. Secretory Phospholipase A 2 Mammalian sPLA 2 s are generally small molecular weight proteins (∼14-19 kDa) with six to eight disulfide bridges. There are more than ten isoforms of sPLA 2 s in mammals including groups IA-B, IIA-F, III, V, IX, X, XIA-B, XII, XIII, and XIV [22, 36] . Recent studies have focused on sPLA 2 -IIA because this sPLA 2 is a pro-inflammatory protein and is upregulated in coronary artery diseases, atherosclerosis, sepsis, arthritis, and infection [37] . In rodents, most studies on sPLA 2 -IIA are limited to rats because many mouse strains lack functional sPLA 2 -IIA [38] . Transgenic mice overexpressing human sPLA 2 -IIA showed increases in hepatic cholesterol and in collagen deposits in macrophages, suggesting a pro-inflammatory role for this protein [39, 40] . Our studies indicated upregulation of sPLA 2 -IIA in reactive astrocytes in response to injury due to focal cerebral ischemia in rats [41] . In a subsequent study, we also showed an increase in sPLA 2 -IIA mRNA expression in AD brain as compared to age-matched controls [42] . These results are in agreement with the recent report indicating an increase in sPLA 2 activity in cerebrospinal fluid of AD patients as compared to healthy control subjects [43] .
Substantial cross-talk seems to exist between the pathways that regulate the expression/activation of cPLA 2 (4) lysophospholipids, e.g., lysophosphatidylcholine, produced by cPLA 2 may alter the membrane microenvironment and thereby further alter membrane protein functions [36, 69] .
The involvement of cPLA 2 in neuronal excitotoxicity, dysfunction, and death in vivo and in vitro has been suggested by several studies. However, despite some indirect evidence, the mechanism whereby cPLA 2 alters mitochondrial membrane and triggers mitochondrial apoptotic pathways remains to be investigated. A study by Kriem et al. demonstrated the role of cPLA 2 in mediating neuronal apoptosis induced by oligomeric Aβ [70] . Using selective inhibitors, cPLA 2 and iPLA 2 were shown to play a role in Aβ-mediated loss of mitochondrial membrane potential and increase in ROS in astrocytes [71] . Neurons from cPLA 2 knockout (KO) mice show less NMDAinduced injury as compared with wild-type controls [72] . Transgenic mice overexpressing human APP in neurons exhibited a reduced deficit in learning, memory, and behavioral dysfunctions and diminished Aβ-induced neurotoxicity when crossed with cPLA2 KO mice [30] . Similar reduction of Aβ-induced neurotoxicity was observed using cPLA2 inhibitors [70] . Furthermore, squalestatin was shown to be neuroprotective against Aβ-induced neurotoxicity by inhibiting cPLA2 activation [73] .
Although there is convincing evidence suggesting a role for glial cell NADPH oxidase in Aβ-induced neurotoxicity [74] , relatively few studies have investigated the role of NADPH oxidase in neurons. Antisense oligonucleotide knockdown of p22phox expression inhibited Aβ-induced neuronal apoptosis [75] . The NADPH oxidase inhibitor apocynin was also effective in diminishing the cytotoxic effects of Aβ [76] . Furthermore, diminished oxidative stress, neurovascular dysfunction, and behavioral deficits were observed in the Tg2576 mouse model of AD when these mice were crossed with gp91phox KO mice [77] .
NADPH Oxidase and cPLA 2 and sPLA 2 in Glial Cells
Relatively high levels of NADPH oxidase are found in astrocytes and microglial cells, as compared with neurons, and ROS produced from glial cells has been shown to cause neuronal damage [74, 78] . ROS produced by NADPH oxidase modulates the cytokine-induced activation of NF-κB, a transcription factor that regulates the expression of pro-inflammatory genes, including cyclooxygenase-2 (COX-2), sPLA 2 -IIA, and inducible nitric oxide synthase (iNOS; Fig. 2 ). Our studies showed that IL-1β-induced sPLA 2 -IIA mRNA and protein expression in rat astrocytes could be inhibited by polyphenol antioxidants and apocynin, a known NADPH oxidase inhibitor [79] . These results are consistent with other studies indicating that Aβ and cytokines potentiate ROS production via NADPH oxidase activation in glial cells [80, 81] . Arachidonic acid is another activator of NADPH oxidase that causes superoxide release from microglia and induces their proliferation [82] . Using neuron-glial cell coculture, peroxynitrite was shown to be produced by NO release from iNOS and ROS from NADPH oxidase in glial cells, and peroxynitrite is the potent cytotoxic factor that kills neurons.
Although studies with phagocytes indicate that cPLA 2 targets NADPH oxidase [83, 84] , the role of cPLA 2 in the activation of NADPH oxidase in neurons and glial cells has not been well characterized. Studies with neutrophils demonstrate the formation of a complex between the C2 domain of cPLA 2 and the p47 phox-PX domain of NADPH oxidase [84] . In BV-2 microglial cells, which lacks sPLA 2 -IIA, Aβ could induce activation of NADPH oxidase and this was linked to a rapid increase in cPLA 2 phosphorylation and a delayed increase in expression which was attributed to the NF-κB pathway. Aβ also enhanced production of PGE 2 through conversion of AA by COX-2. In this study, Aβ also led to induction of iNOS and release of NO, but this was thought to be mediated through activation of the PGE 2 receptor and the downstream PKA-CREB pathway. Interestingly, inhibition of cPLA 2 by antisense led to a decrease in NADPH oxidase activity and release of superoxides, PGE 2 formation, iNOS expression, and NO production [85] . Taken together, this study provided results demonstrating a close relationship between NADPH oxidase and cPLA 2 in Aβ-mediated inflammatory responses in microglial cells.
In wild-type mice, Aβ-induced neurotoxicity is enhanced by microglia that produce superoxide from NADPH oxidase, a response that is inhibited in gp91phox KO mice [78] . Aβ also has been shown to increase ROS production in astrocytes through the calcium-dependent activation of NADPH oxidase, and oxidative stress results in glutathione depletion and neuronal death [86] . Peroxynitrite appears to be an important factor mediating neurotoxicity in vitro [87] since generation of pathophysiological concentrations of superoxide and NO are necessary but not sufficient to induce neurodegeneration [88] . It is noted that these studies do not exclude the possibility that neurotoxicity is mediated by other factors, such as pro-inflammatory cytokines and protein modification through cysteine Snitrosylation [89] [90] [91] [92] . Recognition of the important role of NADPH oxidase in generating ROS that regulate receptor signaling pathways has highlighted an urgent need to develop novel approaches and pharmacological agents to regulate this enzyme system [93, 94] . In this regard, it is important to identify compounds that directly modulate the activities of NADPH oxidase, either through binding to specific protein subunits or through scavenging the ROS produced. The recent study by Jaquet et al. provided a list of small molecules useful as NOX inhibitors [95] . Although compounds such as diphenyleneiodonium, apocynin, atorvastatin, and 4-(2-aminoethyl)benzenesulfonyl fluoride have been used to inhibit NADPH oxidase, these compounds are rather nonspecific. On the other hand, gp91ds-tat, a peptide inhibitor, can specifically block NOX2 [48] . Since different cell types can produce different amount of ROS, it is also important to develop cell-special inhibitors for NADPH oxidase, in particular, for targeting microglial cells [96, 97] . Of particular interest is dextromethorphan, a noncompetitive NMDA receptor antagonist and antitussive agent that has been shown to inhibit several NADPH oxidase-mediated responses, including degeneration of dopaminergic neurons in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinson's model and endotoxic shock in mice [98, 99] . Another approach is to inhibit NADPH oxidase-mediated responses including inflammation and oxidative stress by nutritional means using natural products from plants [100] . Indeed, the use of plant antioxidants has gained considerable popularity in recent years [95] .
Prevention of Neurodegenerative Diseases by Natural Antioxidants
Fruits and vegetables are known to contain phenolic compounds that exhibit antioxidant properties and have been shown to exert health benefits and reduce risk of major diseases, including cardiovascular and neurodegenerative diseases (see review in [101] ). The underlying mechanisms for neuroprotection, however, remain incompletely understood but likely involve the ability of polyphenols and plant extracts to scavenge ROS and counteract Aβ formation/aggregation directly or indirectly [102, 103] . Some phytochemicals may exert neurohormetic effects and protect neurons from injury by upregulating cell survival pathways [104] . There is also evidence that some polyphenols, such as curcumin, may inhibit Aβ fibril formation and destabilize preformed fibril Aβ [102, [105] [106] [107] . Other studies have demonstrated that some natural products provide neuroprotection by targeting multiple cellular signaling pathways [108, 109] . Recent in vitro and in vivo studies have indicated that purified botanical compounds or plant extracts effectively prevent Aβ-induced neurotoxicity (Table 1) as well as provide neuroprotection in animal models of AD ( Tea extracts Hippocampal neurons + [133] as neuroprotective agents [101] , these compounds are not included in Tables 1 and 2 . Dietary flavonoids are potent inhibitors of NADPH oxidase. Figure 3 shows the chemical structures of some flavonoids as described in Table 1 . A study of 45 compounds indicated that flavanols inhibit NADPH oxidase through an apocynin-like mechanism [110] . Other studies demonstrate the ability of dietary polyphenols to inhibit NADPH oxidase, suggesting that these polyphenols may serve as novel therapeutic agents in neuroinflammation [111] . Some polyphenols, like those from grape seed extract, also have been shown to regulate NADPH oxidase subunit expression [112] .
Dreiseitel et al. used a kinetic photometric model to compare the potency of a number of anthocyanidins for inhibition of sPLA 2 [113] . Anthocyanidins have been shown to ameliorate cognitive deficits in AD patients and improve immunocompetency of these patients [114] . The polyphenol genistein was shown to be a potent inhibitor of sPLA 2 in inflammatory exudates and in snake venominduced mouse paw edema [115] . It appears that antiinflammatory activities of many plant flavonoids are associated with inhibition of PLA 2 [116] . These studies provide strong rationale to search for novel compounds as specific inhibitors of PLA2s [117] [118] [119] [120] [121] . 
Summary
In summary, AD progression is marked by an increase in oxidative stress and chronic inflammation that is attributed in part to the toxic effects of Aβ. Studies in recent years have identified NADPH oxidase as an important source of ROS that contributes to Aβ-induced neuronal damage and glial cell activation. ROS produced by NADPH oxidase activate MAPK and subsequently cPLA 2 , a key enzyme that releases AA from phospholipids for the synthesis of eicosanoids (Fig. 1) . cPLA 2 activation and AA release have been associated with neuronal excitotoxicity, impairment of mitochondrial dysfunction, and neuronal apoptosis. In addition, ROS produced by NADPH oxidase can activate NF-κB to promote pro-inflammatory gene transcription, thereby enhancing the synthesis of sPLA 2 , iNOS, and COX-2, enzymes that play a role in neurodegenerative diseases (Fig. 2) . There is compelling evidence for the beneficial effects of antioxidants from botanical sources as inhibitors of NADPH oxidase and PLA 2 , and these polyphenolic compounds may become useful therapeutic agents to alleviate oxidative stress and chronic inflammation in neurodegenerative diseases, including AD.
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